Author

V. Heinemann

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial.

BACKGROUND First-line treatment of PD-L1-positive advanced gastroesophageal adenocarcinoma (GEA) combines doublet 5-FU/platinum with anti-PD1 inhibition. While triplet chemotherapy (FLOT/TFOX) has demonstrated efficacy alone, data on the combination of FLOT with immunotherapy remain sparse. Given the intensity of tripl...

M. Masetti, A. Nieto, Sylvie Lorenzen et al. · European Journal of Cancer · 0 citations

Review Open access Jul 2026

Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis

Monitoring RAS mutations in circulating tumor DNA (ctDNA) is increasingly relevant in metastatic colorectal cancer (mCRC). In patients with tissue RAS wild-type (WT) tumors treated with first-line chemotherapy plus anti-epidermal growth factor receptor therapy (1LChT + anti-EGFR), some studies suggest that RAS WT ctDNA...

M. Valladares-Ayerbes, P. García Alfonso, V. Heinemann et al. · Journal of Gastrointestinal... · 0 citations